Board of Directors

Richard LaferrièreRichard Laferrière

Chairman of the Board of Directors, Warnex Inc.
Executive Chairman, Extenway Solutions Inc.

Mr. Laferrière has been Chairman of the Board of Warnex since 1996. Mr. Laferrière has been Executive Chairman of Extenway Solutions Inc. since May 2008 and Chairman of the Board of FRV Media Inc. since May 2008. From 2000 to 2008, Mr. Laferrière was President and Chief Executive Officer as well as Director of FRV Media Inc. He was also a shareholder and member of the Board of "HR Stratégie", a private equity firm, from 2000 to 2006. He was co-founder and President of Groupe Coscient from 1978 to 1999. In 2007, Mr. Laferrière joined the Board of Directors of Fronsac Capital Inc.


Michael SingerMichael Singer

Chairman of the Executive Committee of the Board of Directors, Warnex Inc.
Chief Financial Officer and Corporate Secretary, Thallion Pharmaceuticals Inc.

Mr. Singer has been Chief Financial Officer and Corporate Secretary of Thallion Pharmaceuticals Inc. since March 2007. Prior to Thallion, he served as Vice President, Chief Financial Officer and Corporate Secretary of Caprion Pharmaceuticals Inc. from February 2000 until its merger with Ecopia BioSciences Inc. to form Thallion in 2007.


Louis LacasseLouis Lacasse

President, Genechem Management Inc.

Mr. Lacasse has been President of GeneChem Management Inc. since 1997 and Managing Partner of AgeChem Financial Inc. since 2006. Mr. Lacasse is currently on the boards of directors of Methylgene Inc. and Calyx Bioventures. He has previously served on the boards of directors of many private and public companies including BioChem Pharma Inc., Axcan Pharma Inc., Targeted Genetics Inc., and Idun Pharmaceuticals Inc.


Mattie ChinksMattie Chinks

President, Avmor Ltd.

Mr. Chinks is President of Avmor Ltd., a leading company in the development and manufacturing of professional cleaning and sanitation products and cleaning solutions. He has over 25 years experience in sales and marketing, product development, general management and corporate development. Mr. Chinks has previously served as President and International Director of the International Sanitary Supply Association and currently sits on the Board of Directors of The Royal Victoria Hospital Foundation and Cannon Hygiene Canada.


Michel LassondeMichel Lassonde


Mr. Lassonde has been a consultant and director of various companies since March 2008. Mr. Lassonde has also been President, CEO and Director of Fronsac Capital Inc. since August 2008. From September 1991 to March 2008, he was a Court of Québec judge. Previously, Mr. Lassonde practiced law for over 25 years. He has a master's degree in international law from New York University.


Patrice HugoPatrice Hugo

Chief Scientific Officer, Clearstone Central Laboratories

Dr. Patrice Hugo has more than 20 years of experience in biomarkers including in the fields of discovery and validation as well as in diagnostic product development. Since 2009, he has been Chief Scientific Officer of Clearstone Central Laboratories, following the spin-off of a business unit of MDS Pharma Services to Global Central Laboratories where he held the position of Vice-President Scientific Affairs since 2008. From 2003 to 2008, Dr. Hugo held various senior roles at Caprion from Executive Director to Executive Vice President Research and Development. From 1997 to 2003, Dr. Hugo worked at PROCREA BioSciences, first as Vice President of Scientific Research and then as Chief Scientific Officer. From 1994 to 1997, he worked as a Principal Investigator at the Institut de Recherches Cliniques de Montréal. Dr. Hugo holds a PhD in Experimental Medicine from McGill University.


Marc LeBelMarc LeBel


Dr. LeBel is currently Director of Acasti Pharma Inc., a member of the Advisory Committee of JustBio, Executive Producer of the film "Ruby McCollum", and Associate Producer of the 3D animation movie "Sarila". He is the founder of Anapharm Inc. and served as the company's President from 1994 to 2007. Dr. LeBel was Executive Vice-President of Pharmanet, from 2005 to 2007, following its acquisition of Anapharm.


Joseph WalewiczJoseph Walewicz


Mr. Joseph Walewicz was Vice-President, Special Projects and COO of Paladin Biosciences between 2009 and 2011. Between 2005 and 2008, Mr. Walewicz was Executive Director, Institutional Equity Research at CIBC World Markets. Mr. Walewicz holds a Master of Business Administration, Finance, a Bachelor of Science, Biochemistry, and a Bachelor of Arts, Economics. Mr. Walewicz is also a CFA (Chartered Financial Analyst) charter holder.

Stock Quote

TSX: WNX   High: 0.02
Open: 0.02 Low: 0.015
Canadian $    Quotes are delayed.


2010 Annual Report (PDF: 643 Kb)
Corporate presentation (PDF: 3.43 Mb)

Latest News

February 2, 2012
Warnex Extends Maturity Date of Its Outstanding Debenture
January 12, 2012
Warnex Comments on its Listing Status